Skip to main content

Galante Joseph C's Form 4 filing

Cumberland Pharmaceuticals Inc (CPIX) ยท filed Sep 30, 2022

Accession no.
0001209191-22-051667
Filed
Sep 30, 2022
Trade date
Aug 16-Sep 27, 2022
Filing delay
45 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 30 non-derivative transactions. Open-market purchases total $4.85K. It was filed 45 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Galante Joseph CCIK 0001632384Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 16, 2022Common StockPPurchaseAcquired+65$2.35+$152.7550,956Direct
Aug 17, 2022Common StockPPurchaseAcquired+65$2.31+$150.1551,021Direct
Aug 18, 2022Common StockPPurchaseAcquired+65$2.23+$144.9551,086Direct
Aug 19, 2022Common StockPPurchaseAcquired+65$2.35+$152.7551,151Direct
Aug 22, 2022Common StockPPurchaseAcquired+65$2.51+$163.1551,216Direct
Aug 23, 2022Common StockPPurchaseAcquired+65$2.59+$168.3551,281Direct
Aug 24, 2022Common StockPPurchaseAcquired+65$2.59+$168.3551,346Direct
Aug 25, 2022Common StockPPurchaseAcquired+65$2.62+$170.351,411Direct
Aug 26, 2022Common StockPPurchaseAcquired+65$2.55+$165.7551,476Direct
Aug 29, 2022Common StockPPurchaseAcquired+70$2.44+$170.851,546Direct
Aug 30, 2022Common StockPPurchaseAcquired+70$2.38+$166.651,616Direct
Aug 31, 2022Common StockPPurchaseAcquired+70$2.36+$165.251,686Direct
Sep 1, 2022Common StockPPurchaseAcquired+70$2.39+$167.351,756Direct
Sep 2, 2022Common StockPPurchaseAcquired+70$2.42+$169.451,826Direct
Sep 6, 2022Common StockPPurchaseAcquired+70$2.15+$150.551,896Direct
Sep 7, 2022Common StockPPurchaseAcquired+70$2.24+$156.851,966Direct
Sep 8, 2022Common StockPPurchaseAcquired+40$2.22+$88.852,036Direct
Sep 9, 2022Common StockPPurchaseAcquired+70$2.21+$154.752,076Direct
Sep 12, 2022Common StockPPurchaseAcquired+70$2.46+$172.252,146Direct
Sep 13, 2022Common StockPPurchaseAcquired+70$2.45+$171.552,216Direct
Sep 14, 2022Common StockPPurchaseAcquired+70$2.51+$175.752,286Direct
Sep 15, 2022Common StockPPurchaseAcquired+70$2.47+$172.952,356Direct
Sep 16, 2022Common StockPPurchaseAcquired+70$2.49+$174.352,426Direct
Sep 19, 2022Common StockPPurchaseAcquired+65$2.56+$166.452,491Direct
Sep 20, 2022Common StockPPurchaseAcquired+65$2.54+$165.152,556Direct
Sep 21, 2022Common StockPPurchaseAcquired+65$2.59+$168.3552,621Direct
Sep 22, 2022Common StockPPurchaseAcquired+65$2.51+$163.1552,686Direct
Sep 23, 2022Common StockPPurchaseAcquired+65$2.55+$165.7552,751Direct
Sep 26, 2022Common StockPPurchaseAcquired+65$2.49+$161.8552,816Direct
Sep 27, 2022Common StockPPurchaseAcquired+65$2.57+$167.0552,881Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)